Atopic Dermatitis

Latest News


Latest Videos



More News

The U.S. Food and Drug Administration has approved a single-dose 300 mg pre-filled pen version of dupilumab (Dupixent, Sanofi and Regeneron) for the treatment of atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) in U.S. patients 12 years and older.

Researchers evaluating several itch assessment tools say there is a need for a better way. Studies comparing the validity and reliability of itch measurement scales are lacking, say researchers who examined several available assessment tools.

Interview with Mark Lebwohl, M.D.

This week, we spoke with Mark Lebwohl, M.D., about his recent article featured in the Journal of the American Academy of Dermatology regarding biologic use in dermatology patients during the COVID-19 pandemic.

atopic dermatitis on arms

Adult patients with moderate-to-severe atopic dermatitis who were treated with systemic agents, including cyclosporine, azathioprine, mycophenolate mofetil, methotrexate or cyclophosphamide, reported a high level of disease-related burden despite those treatments, says a recent study.

Red inflamed skin on arm

Atopic dermatitis therapy is currently undergoing a revolution that promises to treat patients of all ages who are suffering from every aspect of the disease-from rashes, itch and sleep disturbances, to secondary effects, like anxiety and depression.

atopic dermatitis on arms

It’s an exciting time for atopic dermatitis patients as many new treatment options are on the market and in the pipeline. But treatment doesn’t yet offer a cure and many patients continue to suffer with symptoms, including itch, psychosocial and quality-of-life issues, according to a recent paper.